Combination of SAR3419 and Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

NCT01470456 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

50

Enrollment

INDUSTRY

Sponsor class

Conditions

Diffuse Large B-Cell Lymphoma

Interventions

DRUG: SAR3419
DRUG: rituximab

Sponsor

Sanofi